期刊文献+

磷霉素钠联合头孢哌酮/舒巴坦治疗下呼吸道感染疗效观察 被引量:1

Clinical Observation of the Effect of Fosfomycin Sodium Combined with Cefoperazone Sodium and Sulbactam Sodium in Treating Lower Respiratory Tract Infection
原文传递
导出
摘要 目的:观察磷霉素钠联合头孢哌酮钠/舒巴坦钠治疗下呼吸道感染的疗效与安全性。方法:79例下呼吸道感染住(?)患者按入院顺序分为两组,观察组给予磷霉素钠注射剂4.0 g,ivd qd,给药后1h给予头孢哌酮钠/舒巴坦钠注射剂2.0 g,ivd bid;对照组单独应用头孢哌酮钠/舒巴坦钠注射剂2.0 g,ivd bid。两组疗程均为7~14 d,比较两组有效率、细菌清除率及不良反应情况。结果:观察组有效率和细菌清除率分别为92.50%和85.71%,对照组分别为74.35%和62.96%,两组比较,差异均有统计学意义(P<0.05);两组不良反应发生率分别为2.50%和2.56%,差异无统计学意义(P>0.05)。结论:磷霉素钠联合头孢哌酮钠/舒巴坦钠治疗下呼吸道感染,疗效优于单用头孢哌酮钠/舒巴坦钠,且安全性良好,值得临床推广应用。 Objective:To observe the curative effect and security of fosfomycin sodium injection combined with cefoperazone sodium and sulbactam sodium injection in treating lower respiratory tract infection. Methods:79 cases of lower respiratory tract infection were divided into two groups randomly. The treatment group were given fosfomycin sodium injection 4.0g by ivd within 1-2h. 1 hours after administration, cefoperazone sodium and sulbactam sodium injection were given 2.0g by ivd within 30-60min,2 times per day, and the period of treatment was 7-14d. The controlled group were given cef- operazone sodium and sulbactam sodium injection 2.0g by ivd, 2 times per day, the period of treatment was 7-14d. The efficacy, bacterial clearance rate and adverse reaction of the two groups were observed. Results:The effective rates and bacteria elimination rates of the treatment groups were 92.5% and 85.7% respectively and 74.35%, and 62.96% respectively in the controlled group. Significant differences were found through comparison between the two groups(P〈0.05); The incidence of adverse reactions were 2.50% and 2.56% respectively, No significant differences were found between the two groups (P〉0.05). Conclusion:The curative effect of fosfomycin sodium injection combined with cefoperazone sodium and sulbactam sodium injection in treating lower respiratory tract infection was better than that of single cefoperazone sodium and sulbactam sodium injection, and the good security was worthy of clinical application.
机构地区 解放军第
出处 《药物流行病学杂志》 CAS 2013年第8期413-414,429,共3页 Chinese Journal of Pharmacoepidemiology
关键词 磷霉素钠 头孢哌酮钠 舒巴坦钠 下呼吸道感染 疗效 Fosfomycin Sodium Cefoperazone Sodium and Sulbactam Sodium Lower respiratory tract infection Curative effect
  • 相关文献

参考文献7

二级参考文献65

  • 1黄祥,王健民,李勇.磷霉素的药动学药效学特性与临床应用[J].中国医院药学杂志,2005,25(2):156-158. 被引量:62
  • 2卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团重庆出版社,2009:700-701.
  • 3Grif K,Dierich MP,Pfaller K,et al.In vitro activity of fosfomycin in combination with various antistaphyloccal substances[J].J Antimicrob Chemother,2001,48 (2):209 -217.
  • 4Kastoris AC,Rafailidis PI,Vouloumanou EK,et al.Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria[J].Eur J Clin Pharmacol,2010,66(4):359 -368.
  • 5Clinical and Laboratory Standards Instiute (CLSI)/NCCLS[S].Performence stcmdards for antimicrobial susceptibility testing stamdards:nighteenth informational supplement,2009.M100-S19.
  • 6HENDLIN D,STAPLEY E O,JACKSON M,et al.Phos-phonomycin,a new antibiotic produced by strains of streptomyces[J].Science,1969,166 (901):122-123.
  • 7WOODYER R D,SHAO Z,THOMAS P M,et al.Heter-ologous production of fosfomycin and identification of the minimal biosynthetic gene cluster[J].Chem Biol,2006,13(11):1171-1182.
  • 8PATEL S S,BALFOUR J A,BRYSON H M.Fosfomycin tromethamine.A review of its antibacterial activity,pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections[J].Drugs,1997,53(4):637-656.
  • 9POPOVIC M,STEINORT D,PILLAI S,et al.Fosfomycin:an old,new friend?[J].Eur J Clin Microbiol Infect Dis,2010,29(2):127-142.
  • 10FORSGREN A,WALDER M.Antimicrobial activity of fosf-omycin in vitro[J].J Antimicrob Chemother,1983,11(5):467-471.

共引文献519

同被引文献7

引证文献1

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部